New applications of disease genetics and pharmacogenetics to drug development

Allen D. Roses, Ann M. Saunders, Michael W. Lutz, Nanyin Zhang, Ahmad R. Hariri, Karen E. Asin, Donna G. Crenshaw, Kumar Budur, Daniel K. Burns, Stephen K. Brannan

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

TOMMORROW is a Phase III delay of onset clinical trial to determine whether low doses of pioglitazone, a molecule that induces mitochondrial doubling, delays the onset of MCI-AD in normal subjects treated with low dose compared to placebo. BOLD imaging studies in rodents and man were used to find the dose that increases oxygen consumption at central regions of the brain in higher proportion than activation of large corticol regions. The trial is made practical by the use of a pharmacogenetic algorithm based on TOMM40 and APOE genotypes and age to identify normal subjects at high risk of MCI-AD between the ages of 65-83 years within a five year follow-up period.

Original languageEnglish (US)
Pages (from-to)81-89
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2014

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'New applications of disease genetics and pharmacogenetics to drug development'. Together they form a unique fingerprint.

  • Cite this

    Roses, A. D., Saunders, A. M., Lutz, M. W., Zhang, N., Hariri, A. R., Asin, K. E., Crenshaw, D. G., Budur, K., Burns, D. K., & Brannan, S. K. (2014). New applications of disease genetics and pharmacogenetics to drug development. Current Opinion in Pharmacology, 14(1), 81-89. https://doi.org/10.1016/j.coph.2013.12.002